ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 342.29M | 307.96M | 268.06M | 283.99M | 278.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 342.29M | 307.96M | 268.06M | 283.99M | 278.63M |
| Cost of Revenue | 111.37M | 109.87M | 101.66M | 110.98M | 109.48M |
| Gross Profit | 230.92M | 198.09M | 166.40M | 173.01M | 169.16M |
| SG&A Expenses | 159.20M | 160.25M | 171.02M | 155.62M | 133.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 270.57M | 270.12M | 272.68M | 266.60M | 242.88M |
| Operating Income | 71.72M | 37.84M | -4.62M | 17.39M | 35.76M |
| Income Before Tax | 80.44M | 46.47M | 3.98M | 26.32M | 44.60M |
| Income Tax Expenses | 26.92M | 14.97M | 344.00K | -247.25M | -27.18M |
| Earnings from Continuing Operations | 53.52M | 31.50M | 3.64M | 273.57M | 71.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.52M | 31.50M | 3.64M | 273.57M | 71.78M |
| EBIT | 71.72M | 37.84M | -4.62M | 17.39M | 35.76M |
| EBITDA | 75.37M | 40.99M | -1.62M | 20.32M | 38.71M |
| EPS Basic | 0.31 | 0.18 | 0.02 | 1.62 | 0.43 |
| Normalized Basic EPS | 0.29 | 0.17 | 0.01 | 0.10 | 0.17 |
| EPS Diluted | 0.31 | 0.18 | 0.02 | 1.60 | 0.42 |
| Normalized Diluted EPS | 0.29 | 0.17 | 0.01 | 0.10 | 0.16 |
| Average Basic Shares Outstanding | 172.55M | 171.60M | 170.52M | 169.34M | 168.84M |
| Average Diluted Shares Outstanding | 175.47M | 172.85M | 172.71M | 171.36M | 170.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |